Table 3.
Demographic, Trial-, and Cancer-Related Variables Among PCa Survivors Stratified by Trial Arm (unadjusted weighted results)
| Variable | Usual Care(%; n = 260) | Screening(%; n = 269) | P |
|---|---|---|---|
| Age at interview, years | .003* | ||
| Mean | 75.36 | 73.95 | |
| SD | 5.31 | 5.59 | |
| Years since trial enrollment | .100* | ||
| Mean | 11.34 | 11.11 | |
| SD | 1.62 | 1.60 | |
| Years since diagnosis | .063* | ||
| Mean | 7.30 | 7.52 | |
| SD | 1.30 | 1.35 | |
| Race | .638† | ||
| African American | 7.1 | 6.0 | |
| White | 92.9 | 94.0 | |
| Marital status | .170† | ||
| Not married | 20.2 | 15.6‡ | |
| Married | 79.8 | 84.4 | |
| Education level | .100† | ||
| HS or less | 30.7 | 25.7‡ | |
| Some college/trade | 33.3 | 29.1 | |
| BA/BS or higher | 36.0 | 45.2 | |
| Income level | .484† | ||
| < $50,000 | 49.5‡ | 46.3‡ | |
| ≥ $50,000 | 50.5 | 53.7 | |
| Employment status | .488† | ||
| Retired/not employed | 78.1‡ | 75.6‡ | |
| FT/PT | 21.9 | 24.4 | |
| Comorbidities | .722† | ||
| ≤ 1 | 48.8 | 50.4 | |
| ≥ 2 | 51.2 | 49.7 | |
| Accrual round | .281† | ||
| 1: July to December 2007 | 20.8 | 25.7 | |
| 2: January to June 2008 | 24.0 | 26.2 | |
| 3: July to December 2008 | 26.1 | 19.9 | |
| 4: January to June 2009 | 29.2 | 28.2 | |
| Number of PSAs during 3 years before PLCO enrollment | .187† | ||
| 0 | 42.4 | 44.1 | |
| 1 | 35.7 | 41.2 | |
| 2 | 12.8 | 8.5 | |
| 3+ | 9.1 | 6.3 | |
| Screening center | .581† | ||
| Georgetown University | 10.7 | 11.2 | |
| Henry Ford Health System | 14.6 | 15.3 | |
| Marshfield Clinic | 19.4 | 16.0 | |
| University of Minnesota | 43.4 | 41.3 | |
| Washington University | 11.9 | 16.3 | |
| Urination frequency at night before PLCO enrollment, ≥ 1 time | 29.5 | 28.1 | .722† |
| Years since diagnosis | .409† | ||
| 5-5.99 | 22.9 | 17.4 | |
| 6-6.99 | 22.7 | 20.2 | |
| 7-7.99 | 19.2 | 22.4 | |
| 8-8.99 | 20.6 | 24.3 | |
| 9-9.99 | 14.6 | 15.7 | |
| Stage at diagnosis | .965† | ||
| II | 87.5 | 87.6 | |
| III and IV | 12.5 | 12.4 | |
| Treatment modality | .011† | ||
| Surgery only | 33.0‡ | 45.9‡ | |
| Radiation only | 22.4 | 18.8 | |
| Treatment combination, including ADT | 44.6 | 35.2 | |
| PCa recurrence, yes | 12.1 | 10.5 | .556† |
| Gleason score‡ | < .001† | ||
| 3-6 | 61.2 | 77.2 | |
| 7+ | 38.8 | 22.8 | |
| PSA level at diagnosis | < .001† | ||
| ≤ 4.0 | 8.9 | 22.7 | |
| 4.01-10.0 | 67.8 | 64.8 | |
| ≥ 10.01 | 23.3 | 12.5 |
Abbreviations: ADT, androgen-deprivation therapy; FT/PT, full time/part time; HS, high school; PCa, prostate cancer; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; PSA, prostate-specific antigen; SD, standard deviation.
*
t test.
†
χ2 test.
‡
Columns do not add to 100% because of < 1% missing data.